Meropenem Puren

Meropenem, the active ingredient in Meropenem Puren, is a carbapenem antibiotic presented as a sterile powder for intravenous injection. It is used to treat severe bacterial infections such as complicated intra‑abdominal infections, complicated urinary tract infections, nosocomial pneumonia and septicemia in adult patients.

GNH USA supplies Meropenem Puren as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Meropenem is a broad‑spectrum carbapenem antibiotic indicated for serious bacterial infections affecting various organ systems.

- Complicated intra‑abdominal infections: eradicates mixed aerobic and anaerobic pathogens, helping resolve infection and prevent progression. - Complicated urinary tract infections: eliminates causative Gram‑negative and Gram‑positive bacteria, facilitating clinical cure. - Nosocomial pneumonia: provides coverage against resistant respiratory pathogens, improving pulmonary outcomes. - Septicemia: rapidly clears bloodstream infection, supporting hemodynamic stability.

Meropenem may be associated with a range of adverse reactions, varying in frequency and severity.

Common Side Effects: - Diarrhea: mild to moderate loose stools. - Nausea: feeling of queasiness. - Vomiting: expulsion of stomach contents. - Rash: skin erythema or itching. - Headache: mild to moderate head pain. - Infusion site reactions: erythema or phlebitis at the injection site.

Serious or Rare Side Effects: - Seizures: especially in patients with renal impairment or CNS disorders. - Anaphylaxis: severe allergic reaction with respiratory and circulatory compromise. - Clostridioides difficile colitis: severe diarrhea due to bacterial overgrowth. - Renal impairment: worsening kidney function. - Hepatic enzyme elevation: increased ALT/AST levels. - Thrombocytopenia: reduced platelet count.

When using Meropenem, clinicians should consider several safety measures.

- Renal function: adjust dose in patients with impaired renal clearance. - Seizure risk: monitor patients with pre‑existing central nervous system disorders. - Allergy: avoid in individuals with known hypersensitivity to β‑lactam antibiotics. - Superinfection: watch for overgrowth of non‑susceptible organisms such as fungi. - Pregnancy and lactation: use only if the potential benefit justifies the potential risk to the fetus or infant. - Store at below 25°C: keep in the original container, protect from moisture and light.

Meropenem can interact with other medicines, requiring attention to the level of risk.

Major Interactions (Avoid): - Valproic acid: concomitant use may reduce serum valproate levels and precipitate seizures. - Probenecid: may increase meropenem plasma concentrations, raising the risk of toxicity.

Moderate Interactions (Monitor Closely): - Aminoglycosides: additive nephrotoxicity; monitor renal function. - Loop diuretics: may increase the risk of ototoxicity when combined with other ototoxic agents. - Anticoagulants: may enhance anticoagulant effect; monitor coagulation parameters. - Phenytoin: may reduce meropenem efficacy; consider therapeutic drug monitoring.